Hiperbilirrubinemia neonatal no hemolítica

Referencias

1. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001; 344(8): 581–590
2. Dennery PA, Weng YH, Stevenson DK, Yang G. The biology of bilirubin production. J Perinatol. 2001; 21(suppl 1): S17–20; discussion S35–19
3. Kaplan M, Muraca M, Hammerman C, et al. Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics. 2002; 110(4). Available at: www.pediatrics.org/cgi/content/full/110/4/e47
4. Stevenson DK, Dennery PA, Hintz SR. Understanding newborn jaundice. J Perinatol. 2001; 21(suppl 1):S21–24; discussion S35–29
5. Ip S, Lau J, Chung M, et al. Hyperbilirubinemia and kernicterus: 50 years later. Pediatrics. 2004; 114(1): 263–264
6. Newman TB, Liljestrand P, Jeremy RJ, et al; Jaundice and Infant Feeding Study Team. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006; 354(18):1889–1900
7. Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr. 2000; 89(10):1213–1217
8. Ip S, Chung M, Kulig J, et al; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004; 114(1). 
Available at: www.pediatrics.org/cgi/content/full/114/1/e130
9. Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 2002; 140(4):396–403 PEDIATRICS Volume 136, number 6, December 2015 1093
10. Bhutani VK, Maisels MJ, Stark AR, Buonocore G; Expert Committee for Severe Neonatal Hyperbilirubinemia; European Society for Pediatric Research; American Academy of Pediatrics.
Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants or =35 weeks gestation. Neonatology. 2008; 94(1):63–67
11. Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS. Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. Arch Dis
Child. 2005; 90(4):415–421
12. Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med. 2000; 154(11):1140–1147
13. Schwartz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia: current guidelines and emerging therapies. Pediatr Emerg Care. 2011; 27(9):884–889
14. Smitherman H, Stark AR, Bhutani VK. Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med. 2006; 11(3):214–224
15. Stark AR, Lannon CM. Systems changes to prevent severe hyperbilirubinemia and promote breastfeeding: pilot approaches. J Perinatol. 2009; 29 (suppl 1):S53–57
16. Stevenson DK, Fanaroff AA, Maisels MJ, et al Prediction of hyperbilirubinemia in near-term and term infants. J Perinatol. 2001; 21 (suppl 1):S63–72; discussion S83–67
17. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004; 114(1): 297–316
18. Ip S, Glicken S, Kulig J, Obrien R, Sege R, Lau J. Management of Neonatal Hyperbilirubinemia. Pub 03-E011. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2003
19. Berk MA, Mimouni F, Miodovnik M, Hertzberg V, Valuck J. Macrosomia in infants of insulin-dependent diabetic mothers. Pediatrics. 1989; 83(6): 1029–1034
20. Peevy KJ, Landaw SA, Gross SJ. Hyperbilirubinemia in infants of diabetic mothers. Pediatrics. 1980; 66(3):417–419
21. Gale R, Seidman DS, Dollberg S, Stevenson DK. Epidemiology of neonatal jaundice in the Jerusalem population. J Pediatr Gastroenterol Nutr. 1990; 10(1):82–86
22. Maisels MJ, Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics. 1998; 101(6):995–998
23. Laopaiboon M, Lumbiganon P, Intarut N, et al; WHO Multicountry Survey on Maternal Newborn Health Research Network. Advanced maternal age and pregnancy outcomes: a multicountry assessment. BJOG. 2014; 121 (suppl 1):49–56
24. Scott-Pillai R, Spence D, Cardwell CR, Hunter A, Holmes VA. The impact of body mass index on maternal and neonatal outcomes: a retrospective study in a UK obstetric population, 2004–2011. BJOG. 2013; 120(8):932–939
25. OECD. Caesarean sections. In: Health at a Glance 2013: OECD Indicators. Paris, France: OECD Publishing; 2013. Available at: http://dx.doi.org/10.1787/health_glance-2013-en
26. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996; 85(7): 843–848
27. Norman M, Karlsson H, Sarman I, Engberg S, Ewald U. Vårdprogram: neonatal hyperbilirubinemia (Swedish guideline for neonatal hyperbillrubinemia, bilirubin chart for term infants). 2008 
Available at: http://neoforeningen.se/dokument/vardprogram/hyperbili_kurva_2008.pdf
28. Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006; 117(5). Available at: www.pediatrics.org/cgi/content/full/117/5/e855
29. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant or =35 weeks’ gestation: an update with clarifications. Pediatrics. 2009; 124(4):1193–1198
30. Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani VK. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics. 2008; 121(1). Available at: www.pediatrics.org/cgi/ content/full/121/1/e170
31. Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med. 2005; 159(2):113–119
32. Maisels MJ, Deridder JM, Kring EA, Balasubramaniam M. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia. J Perinatol. 2009; 29(9):612–617
33. Bhutani VK, Stark AR, Lazzeroni LC, et al; Initial Clinical Testing Evaluation and Risk Assessment for Universal Screening for Hyperbilirubinemia Study Group. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr. 2013; 162(3):477–482.e1
34. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ. 2006; 175(6):587–590
35. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008; 358(9):920–928
36. Hansen TW. Therapeutic approaches to neonatal jaundice: an international survey. Clin Pediatr (Phila). 1996; 35(6): 309–316
37. Martin JA, Hamilton BE, Osterman MJK, et al. Births: Final Data for 2013. National Vital Statistics Reports 64(1). Hyattsville, MD: National Center for Health Statistics; 2015. Available at: www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_01.pdf
38. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012; 307(5):491–497
39. Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr. 2011; 100(4): 499–505